| Sensabues AB (“Sensabues”), the Company’s wholly-owned subsidiary, owns the core intellectual properties for the design of sample collection devices and the methodologies to collect, extract and detect the non-volatile substances presented within aerosols in exhaled breath. Subsequent to the six months ended October 31, 2023, due to the difficulties in raising adequate capital, the significant cost of maintaining the patents, and delays in engaging appropriate commercialization partners, the management of the Company believed that its current business of commercializing the exhale breath technology patents was no longer feasible. During the three months ended January 31, 2024, the Company began winding-up the business of Sensabues to reduce operating expenses associated with maintaining the exhale breath technology patents. Since then, management of the Company has been in the process of establishing a new business segment to develop energy related businesses which led to the entry into an agreement and plan of merger, on December 11, 2023, by and among the Company, Formation Minerals, Inc., a Nevada corporation and a direct, wholly-owned subsidiary of the Company (“Merger Sub”), and Verde Bio Holdings, Inc. (“Verde”), a Nevada Corporation, as amended as of February 8, 2024, pursuant to which Merger Sub would merge with and into Verde, with Verde surviving as a direct, wholly owned subsidiary of the Company, and the surviving corporation of the merger (the “Merger”). As of February 26, 2024, Sensabues is no longer under the control of the Company and will cease to exist upon the completion of bankruptcy procedures and therefore was deconsolidated from the Company’s financial statements for the nine months ended January 31, 2024. As a result of the deconsolidation of Sensabues, the Company anticipates significant change in results of operations from the corresponding period for the last fiscal year which will be reflected in the consolidated statements of loss to be included in the Form 10-Q. We expect to report total revenue of $811,000 for the three months ended January 31, 2024 as compared to $680,000 for the three months ended January 31, 2023, and $1,146,000 for the nine months ended January 31, 2024 as compared to $4,414,000 for the nine months ended January 31, 2023. We expect to report total operating expenses of $519,442 for the three months ended January 31, 2024 as compared to $157,447 for the three months ended January 31, 2023, and $1,191,250 for the nine months ended January 31, 2024 as compared to $490,495 for the nine months ended January 31, 2023. Further, we expect to report net losses of $881,890 for the three months ended January 31, 2024 as compared to $153,406 for the three months ended January 31, 2023, and $1,189,449 for the nine months ended January 31, 2024 as compared to $480,657 for the nine months ended January 31, 2023. |